Tag Archives: type 2 diabetes

August, 2018

3 August
PDL BioPharma Acquires Depomed’s Remaining 50% Interest in Royalties and Milestones on Type 2 Diabetes Products

INCLINE VILLAGE, Nev., Aug. 2, 2018 /PRNewswire/ — PDL BioPharma, Inc. (“PDL”) (NASDAQ: PDLI) announces an amendment to the Royalty Purchase and Sale Agreement (the “Royalty Agreement”) with Depomed, Inc. (“Depomed”) under which PDL acquired all of Depomed’s remaining rights to royalties and milestones payable on sales of type 2 diabetes products licensed by Depomed for up to $20 million. Under …
Share

5 April
FDA Approves Bydureon for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced the US Food and Drug Administration (FDA) has approved BYDUREON® (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes (T2D) with inadequate glycemic control. BYDUREON is approved for adults with T2D whose blood sugar remains uncontrolled on …
Share

27 December
INSYS’ Cannabidiol Solution Receives FDA Fast Track Designation as Treatment for Prader-Willi Syndrome

PHOENIX, Dec. 26, 2017 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder characterized by insatiable appetite in children that …
Share
22 December
FDA Approves Merck and Pfizer’s SGLT2 Drug for Treatment of Type 2 Diabetes

KENILWORTH, N.J. & NEW YORK–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced that the U.S. Food and Drug Administration (FDA) has approved STEGLATROTM(ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN™ (ertugliflozin and sitagliptin) tablets. …
Share

23 October
FDA Approves New Once-Weekly Bydureon BCise Injectable Medicine for Type 2 Diabetes

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BYDUREON® BCise™ (exenatide extended-release) injectable suspension, a new formulation of BYDUREON® (exenatide extended-release) injectable suspension in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines …
Share

19 July
CDC Report Finds More than 100 Million Americans have Diabetes or Prediabetes

ATLANTA, July 18, 2017 /PRNewswire-USNewswire/ — More than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report released today by the Centers for Disease Control and Prevention (CDC). The report finds that as of 2015, 30.3 million Americans – 9.4 percent of the …
Share

12 June
Merck and Pfizer Announce Investigational SGLT-2 Inhibitor Met Primary Endpoint in Two Phase 3 Studies

KENILWORTH, N.J. & NEW YORK–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS MET and VERTIS SITA) of ertugliflozin, an investigational oral SGLT-2 inhibitor in development to help improve glycemic control in adults …
Share

23 January
Enteris BioPharma and Sanofi Enter Deal to Develop Oral Diabetes Drug

BOONTON, N.J., Jan. 23, 2017 /PRNewswire/ — Enteris BioPharma, Inc., announced today the initiation of a feasibility study agreement with Sanofi to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform, Peptelligence™, to develop an oral formulation of one of Sanofi’s preclinical stage peptides. Joel Tune, Chief …
Share

14 December
FDA Approves Synjardy XR Tablets for Adults with Type 2 Diabetes

RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 12, 2016 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Synjardy® XR (empagliflozin and metformin hydrochloride extended-release) tablets for adults with type 2 diabetes. When used along with diet and exercise, SYNJARDY XR is indicated to improve blood sugar in adults with …
Share
5 December
FDA Approves Jardiance to Reduce CV Risk in Patients with Type 2 Diabetes

RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 5, 2016 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) approved a new indication for Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. JARDIANCE is the first type 2 diabetes treatment approved with …
Share

Page 1 of 212 »